Merck To Begin Phase 3 Program With Lower Dose Of Islatravir

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) said it will initiate a phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection. The new phase 3 studies will

Related Keywords

, Merck , Begin , Hase , Program , Ith , Tower , Nose , Islatravir , Oravirine ,